429 is the total number of securities Cormorant Asset Management, LP has owned. The longest Cormorant Asset Management, LP has owned a single stock is 30 quarters.
Period | Weighting | Quarter | |||||||
---|---|---|---|---|---|---|---|---|---|
Ticker | Name | Longest | Shortest | Min. | Avg. | Max. | First | Latest | ↓ Count |
QTNT | QUOTIENT LTD | 30 | 30 | 0.10% | 1.84% | 4.33% | Q2 2014 | Q3 2021 | 30 |
ASND | ASCENDIS PHARMA A/S | 21 | 9 | 0.12% | 0.99% | 4.77% | Q1 2015 | Q4 2022 | 30 |
NERV | MINERVA NEUROSCIENCES INC | 29 | 29 | 0.01% | 0.96% | 4.36% | Q3 2014 | Q3 2021 | 29 |
XLRN | ACCELERON PHARMA INC | 22 | 6 | 0.06% | 0.90% | 3.44% | Q2 2014 | Q2 2021 | 28 |
OMER | OMEROS CORP | 19 | 8 | 0.53% | 2.16% | 6.49% | Q1 2014 | Q3 2021 | 27 |
MRTX | MIRATI THERAPEUTICS INC | 22 | 3 | 0.32% | 3.05% | 7.59% | Q3 2015 | Q4 2022 | 25 |
BPMC | BLUEPRINT MEDICINES CORP | 22 | 3 | 0.29% | 1.56% | 3.55% | Q2 2015 | Q3 2021 | 25 |
APLS | APELLIS PHARMACEUTICAL... | 24 | 24 | 1.24% | 4.27% | 8.56% | Q4 2017 | Q3 2023 | 24 |
NBIX | NEUROCRINE BIOSCIENCES... | 24 | 24 | 0.10% | 2.08% | 4.57% | Q2 2014 | Q1 2020 | 24 |
RCKT | ROCKET PHARMACEUTICALS... | 23 | 23 | 0.54% | 1.43% | 2.40% | Q1 2018 | Q3 2023 | 23 |
ANAB | ANAPTYSBIO INC | 22 | 22 | 0.08% | 3.01% | 13.20% | Q1 2017 | Q2 2022 | 22 |
NKTR | NEKTAR THERAPEUTICS | 14 | 8 | 0.01% | 2.84% | 20.30% | Q3 2014 | Q1 2021 | 22 |
SRNE | SORRENTO THERAPEUTICS INC | 14 | 8 | 0.12% | 1.57% | 4.56% | Q1 2014 | Q3 2021 | 22 |
AGEN | AGENUS INC | 14 | 7 | 0.42% | 0.95% | 1.79% | Q1 2014 | Q3 2021 | 21 |
AUTL | AUTOLUS THERAPEUTICS PLC | 19 | 2 | 0.05% | 0.49% | 3.02% | Q2 2018 | Q3 2023 | 21 |
MYOK | MYOKARDIA INC | 20 | 20 | 1.22% | 2.48% | 8.11% | Q4 2015 | Q3 2020 | 20 |
HRTX | HERON THERAPEUTICS INC | 20 | 20 | 0.25% | 2.48% | 6.57% | Q2 2014 | Q1 2019 | 20 |
ACRS | ACLARIS THERAPEUTICS I... | 16 | 4 | 0.02% | 1.48% | 3.57% | Q4 2015 | Q4 2021 | 20 |
AXNX | AXONICS MODULATION TEC... | 20 | 20 | 0.69% | 1.32% | 2.95% | Q4 2018 | Q3 2023 | 20 |
ARRY | ARRAY BIOPHARMA INC | 12 | 8 | 0.59% | 1.10% | 2.54% | Q4 2013 | Q2 2019 | 20 |
SGMO | SANGAMO THERAPEUTICS INC | 11 | 8 | 0.18% | 0.82% | 2.49% | Q4 2013 | Q4 2018 | 19 |
BBIO | BRIDGEBIO PHARMA INC | 18 | 18 | 0.70% | 3.20% | 7.17% | Q2 2019 | Q3 2023 | 18 |
TBPH | THERAVANCE BIOPHARMA INC | 11 | 7 | 0.05% | 2.58% | 7.62% | Q2 2016 | Q2 2021 | 18 |
STOK | STOKE THERAPEUTICS INC | 18 | 18 | 0.25% | 1.48% | 3.13% | Q2 2019 | Q3 2023 | 18 |
YMAB | Y-MABS THERAPEUTICS INC | 18 | 18 | 0.05% | 1.03% | 2.60% | Q3 2018 | Q4 2022 | 18 |
HARP | HARPOON THERAPEUTICS INC | 18 | 18 | 0.02% | 0.25% | 0.54% | Q1 2019 | Q2 2023 | 18 |
RETA | REATA PHARMACEUTICALS ... | 17 | 17 | 0.41% | 2.39% | 6.66% | Q3 2017 | Q3 2021 | 17 |
BHVN | BIOHAVEN PHARMACTL HLD... | 14 | 3 | 0.30% | 1.66% | 3.90% | Q4 2017 | Q3 2022 | 17 |
ORTX | ORCHARD THERAPEUTICS PLC | 17 | 17 | 0.01% | 0.17% | 0.79% | Q4 2018 | Q4 2022 | 17 |
BCEL | ATRECA INC | 17 | 17 | 0.02% | 0.14% | 0.48% | Q2 2019 | Q2 2023 | 17 |
PTLA | PORTOLA PHARMACEUTICAL... | 16 | 16 | 0.56% | 2.69% | 8.38% | Q4 2013 | Q3 2017 | 16 |
CABA | CABALETTA BIO INC | 16 | 16 | 0.05% | 0.81% | 2.56% | Q4 2019 | Q3 2023 | 16 |
COLL | COLLEGIUM PHARMACEUTIC... | 16 | 16 | 0.20% | 0.76% | 1.59% | Q2 2015 | Q1 2019 | 16 |
ZLAB | ZAI LABS LTD | 16 | 16 | 0.32% | 0.73% | 1.59% | Q3 2017 | Q2 2021 | 16 |
XFOR | X4 PHARMACEUTICALS INC... | 10 | 6 | 0.01% | 0.16% | 0.77% | Q1 2019 | Q1 2023 | 16 |
EGRX | EAGLE PHARMACEUTICALS INC | 15 | 15 | 0.96% | 2.75% | 4.64% | Q1 2014 | Q3 2017 | 15 |
TSRO | TESARO INC | 11 | 4 | 1.49% | 2.41% | 5.42% | Q4 2013 | Q4 2018 | 15 |
DXCM | DEXCOM INC | 15 | 15 | 0.72% | 1.61% | 3.08% | Q4 2013 | Q2 2017 | 15 |
CFRX | CONTRAFECT CORP | 15 | 15 | 0.13% | 0.52% | 1.05% | Q2 2015 | Q4 2018 | 15 |
GOSS | GOSSAMER BIO INC | 15 | 15 | 0.06% | 0.44% | 2.68% | Q1 2019 | Q3 2022 | 15 |
ALDR | ALDER BIOPHARMACEUTICA... | 14 | 14 | 0.39% | 3.22% | 6.10% | Q2 2014 | Q3 2017 | 14 |
ARDX | ARDELYX INC | 14 | 14 | 0.40% | 2.35% | 4.09% | Q3 2014 | Q4 2017 | 14 |
RNA | AVIDITY BIOSCIENCES INC | 14 | 14 | 0.66% | 2.23% | 4.10% | Q2 2020 | Q3 2023 | 14 |
SAGE | SAGE THERAPEUTICS INC | 7 | 3 | 0.01% | 1.69% | 4.56% | Q3 2014 | Q3 2019 | 14 |
ARGX | ARGENX SE | 14 | 14 | 0.18% | 1.19% | 3.51% | Q4 2017 | Q1 2021 | 14 |
SRPT | SAREPTA THERAPEUTICS I... | 10 | 4 | 0.12% | 1.06% | 2.42% | Q4 2018 | Q2 2023 | 14 |
REPH | RECRO PHARMA INC | 14 | 14 | 0.31% | 0.80% | 1.50% | Q1 2014 | Q2 2017 | 14 |
INSP | INSPIRE MED SYS INC | 14 | 14 | 0.32% | 0.61% | 1.00% | Q2 2018 | Q3 2021 | 14 |
AKRO | AKERO THERAPEUTICS INC | 13 | 1 | 0.29% | 0.59% | 1.03% | Q2 2019 | Q2 2023 | 14 |
CRIS | CURIS INC | 14 | 14 | 0.14% | 0.57% | 1.16% | Q2 2014 | Q3 2017 | 14 |
APTOSE BIOSCIENCES INC | 11 | 3 | 0.15% | 0.47% | 0.99% | Q4 2014 | Q3 2021 | 14 | |
AGRX | AGILE THERAPEUTICS INC | 14 | 14 | 0.14% | 0.42% | 0.98% | Q2 2014 | Q3 2017 | 14 |
TPTX | TURNING POINT THERAPEU... | 13 | 13 | 5.80% | 8.00% | 14.14% | Q2 2019 | Q2 2022 | 13 |
TCDA | TRICIDA INC | 13 | 13 | 0.05% | 1.22% | 2.67% | Q2 2018 | Q2 2021 | 13 |
RARE | ULTRAGENYX PHARMACEUTI... | 13 | 13 | 0.67% | 1.10% | 1.68% | Q1 2014 | Q1 2017 | 13 |
ALXO | ALX ONCOLOGY HLDGS INC | 13 | 13 | 0.17% | 1.02% | 3.04% | Q3 2020 | Q3 2023 | 13 |
BOLD | AUDENTES THERAPEUTICS,... | 13 | 13 | 0.09% | 0.73% | 1.60% | Q3 2016 | Q3 2019 | 13 |
GLYC | GLYCOMIMETICS INC | 13 | 13 | 0.19% | 0.53% | 1.76% | Q1 2014 | Q1 2017 | 13 |
ARNA | ARENA PHARMACEUTICALS INC | 13 | 13 | 0.03% | 0.52% | 1.45% | Q1 2018 | Q1 2021 | 13 |
IMDZ | IMMUNE DESIGN CORP | 13 | 13 | 0.32% | 0.47% | 0.73% | Q3 2014 | Q3 2017 | 13 |
DTIL | PRECISION BIOSCIENCES,... | 13 | 13 | 0.07% | 0.21% | 0.95% | Q1 2019 | Q1 2022 | 13 |
CLRBW | CELLECTAR BIOSCIENCES INC | 13 | 13 | 0.00% | 0.00% | 0.00% | Q2 2016 | Q2 2019 | 13 |
RVMD | REVOLUTION MEDICINES INC | 12 | 12 | 2.35% | 3.15% | 3.91% | Q1 2020 | Q4 2022 | 12 |
NVRO | NEVRO CORP | 12 | 12 | 0.06% | 3.02% | 5.89% | Q4 2014 | Q3 2017 | 12 |
CCXI | CHEMOCENTRYX INC | 9 | 3 | 0.75% | 2.28% | 4.58% | Q1 2019 | Q2 2022 | 12 |
GLPG | GALAPAGOS NV | 7 | 5 | 0.71% | 1.97% | 3.80% | Q2 2016 | Q3 2020 | 12 |
OLMA | OLEMA PHARMACEUTICALS INC | 12 | 12 | 0.34% | 1.75% | 3.53% | Q4 2020 | Q3 2023 | 12 |
TARS | TARSUS PHARMACEUTICALS... | 12 | 12 | 1.18% | 1.73% | 2.72% | Q4 2020 | Q3 2023 | 12 |
CBPO | CHINA BIOLOGIC PRODUCT... | 12 | 12 | 0.93% | 1.48% | 1.92% | Q2 2014 | Q1 2017 | 12 |
BCAB | BIOATLA INC | 12 | 12 | 0.12% | 1.34% | 2.81% | Q4 2020 | Q3 2023 | 12 |
MYOV | MYOVANT SCIENCES LTD | 8 | 1 | 0.17% | 0.76% | 1.97% | Q4 2016 | Q3 2021 | 12 |
PLRX | PLIANT THERAPEUTICS, INC | 12 | 12 | 0.26% | 0.71% | 2.53% | Q2 2020 | Q1 2023 | 12 |
INTEC PHARMA LTD JERUS... | 12 | 12 | 0.25% | 0.59% | 1.28% | Q3 2015 | Q2 2018 | 12 | |
NSTG | NANOSTRING TECHNOLOGIE... | 12 | 12 | 0.07% | 0.46% | 1.90% | Q1 2014 | Q4 2016 | 12 |
ABEO | ABEONA THERAPEUTICS INC | 12 | 12 | 0.03% | 0.45% | 1.20% | Q4 2016 | Q3 2019 | 12 |
AQXP | AQUINOX PHARMACEUTICAL... | 12 | 12 | 0.14% | 0.36% | 0.75% | Q1 2014 | Q4 2016 | 12 |
OTLKW | OUTLOOK THERAPEUTICS INC | 8 | 4 | 0.00% | 0.00% | 0.01% | Q4 2018 | Q4 2021 | 12 |
AVIR | ATEA PHARMACEUTICALS INC | 11 | 11 | 0.32% | 2.82% | 8.82% | Q4 2020 | Q2 2023 | 11 |
EWTX | EDGEWISE THERAPEUTICS INC | 11 | 11 | 0.98% | 2.06% | 3.49% | Q1 2021 | Q3 2023 | 11 |
ALNY | ALNYLAM PHARMACEUTICAL... | 6 | 1 | 0.77% | 1.85% | 4.66% | Q4 2013 | Q2 2017 | 11 |
CHRS | COHERUS BIOSCIENCES INC | 11 | 11 | 0.56% | 1.58% | 2.19% | Q4 2014 | Q2 2017 | 11 |
NVAX | NOVAVAX INC | 11 | 11 | 1.04% | 1.57% | 2.37% | Q4 2013 | Q2 2016 | 11 |
AVRO | AVROBIO INC | 11 | 11 | 0.08% | 1.10% | 5.03% | Q2 2018 | Q4 2020 | 11 |
TWST | TWIST BIOSCIENCE CORP | 11 | 11 | 0.51% | 0.97% | 1.46% | Q4 2018 | Q2 2021 | 11 |
PHVS | PHARVARIS N V | 11 | 11 | 0.43% | 0.83% | 1.92% | Q1 2021 | Q3 2023 | 11 |
QURE | UNIQURE NV | 11 | 11 | 0.06% | 0.80% | 2.69% | Q2 2019 | Q4 2021 | 11 |
IGMS | IGM BIOSCIENCES INC | 11 | 11 | 0.17% | 0.78% | 1.26% | Q3 2019 | Q1 2022 | 11 |
LBPH | LONGBOARD PHARMACEUTIC... | 11 | 11 | 0.46% | 0.71% | 0.97% | Q1 2021 | Q3 2023 | 11 |
DERM | DERMIRA INC | 11 | 11 | 0.40% | 0.63% | 0.84% | Q4 2014 | Q2 2017 | 11 |
GNVC | GENVEC INC | 11 | 11 | 0.05% | 0.42% | 0.90% | Q1 2014 | Q3 2016 | 11 |
GLTO | GALECTO INC | 11 | 11 | 0.08% | 0.22% | 0.63% | Q4 2020 | Q2 2023 | 11 |
AGTC | APPLIED GENETIC TECHNO... | 11 | 11 | 0.02% | 0.19% | 1.34% | Q2 2014 | Q4 2016 | 11 |
DSGN | DESIGN THERAPEUTICS INC | 10 | 10 | 1.82% | 4.24% | 6.93% | Q1 2021 | Q2 2023 | 10 |
BMEA | BIOMEA FUSION INC | 10 | 10 | 1.09% | 2.71% | 7.29% | Q2 2021 | Q3 2023 | 10 |
AMAM | AMBRX BIOPHARMA INC | 10 | 10 | 0.18% | 2.66% | 8.87% | Q2 2021 | Q3 2023 | 10 |
CLSD | CLEARSIDE BIOMEDICAL INC | 10 | 10 | 0.16% | 2.08% | 3.80% | Q2 2016 | Q3 2018 | 10 |
AVTE | AEROVATE THERAPEUTICS INC | 10 | 10 | 1.24% | 2.05% | 3.84% | Q2 2021 | Q3 2023 | 10 |
BCRX | BIOCRYST PHARMACEUTICA... | 10 | 10 | 0.46% | 1.71% | 3.95% | Q4 2013 | Q1 2016 | 10 |
PTGX | PROTAGONIST THERAPEUTI... | 8 | 2 | 0.19% | 1.40% | 2.58% | Q3 2016 | Q2 2023 | 10 |
EIDX | EIDOS THERAPEUTICS INC | 10 | 10 | 0.25% | 1.17% | 2.50% | Q2 2018 | Q3 2020 | 10 |
ZYME | ZYMEWORKS INC | 9 | 1 | 0.32% | 1.16% | 2.06% | Q2 2017 | Q4 2021 | 10 |
AXSM | AXSOME THERAPEUTICS INC | 6 | 1 | 0.25% | 1.11% | 2.48% | Q4 2019 | Q2 2023 | 10 |
VERV | VERVE THERAPEUTICS INC | 10 | 10 | 0.27% | 1.00% | 2.43% | Q2 2021 | Q3 2023 | 10 |
FWP | FORWARD PHARMA A/S-ADR | 10 | 10 | 0.48% | 1.00% | 1.84% | Q4 2014 | Q1 2017 | 10 |
VRDN | VIRIDIAN THERAPEUTICS INC | 10 | 10 | 0.17% | 0.97% | 2.15% | Q1 2021 | Q2 2023 | 10 |
PFNX | PFENEX INC | 10 | 10 | 0.38% | 0.91% | 1.61% | Q1 2015 | Q2 2017 | 10 |
ALLK | ALLAKOS INC | 10 | 10 | 0.06% | 0.90% | 2.13% | Q4 2018 | Q1 2021 | 10 |
RGLS | REGULUS THERAPEUTICS INC | 10 | 10 | 0.03% | 0.87% | 2.72% | Q4 2013 | Q1 2016 | 10 |
CNTA | CENTESSA PHARMACEUTICA... | 10 | 10 | 0.12% | 0.79% | 1.72% | Q2 2021 | Q3 2023 | 10 |
LPCN | LIPOCINE INC NEW | 10 | 10 | 0.32% | 0.68% | 1.26% | Q1 2015 | Q2 2017 | 10 |
GHRS | GH RESEARCH PLC | 10 | 10 | 0.31% | 0.50% | 0.85% | Q2 2021 | Q3 2023 | 10 |
AKUS | AKOUOS INC | 10 | 10 | 0.14% | 0.23% | 0.43% | Q2 2020 | Q3 2022 | 10 |
ONSIW | ONCOBIOLOGICS INC - CW... | 10 | 10 | 0.00% | 0.01% | 0.05% | Q2 2016 | Q3 2018 | 10 |
RXDX | PROMETHEUS BIOSCIENCES... | 9 | 9 | 0.82% | 5.92% | 15.38% | Q1 2021 | Q1 2023 | 9 |
ERASCA INC | 9 | 9 | 1.24% | 4.87% | 9.74% | Q3 2021 | Q3 2023 | 9 | |
DYAX | DYAX CORP | 9 | 9 | 2.95% | 4.42% | 6.30% | Q4 2013 | Q4 2015 | 9 |
ALKS | ALKERMES PLC | 9 | 9 | 0.88% | 4.19% | 6.65% | Q1 2014 | Q1 2016 | 9 |
FMTX | FORMA THERAPEUTICS HLD... | 9 | 9 | 1.65% | 3.98% | 6.40% | Q2 2020 | Q2 2022 | 9 |
DRNA | DICERNA PHARMACEUTICAL... | 5 | 4 | 0.32% | 1.97% | 3.53% | Q4 2014 | Q4 2018 | 9 |
IMMUNEERING CORP | 9 | 9 | 0.74% | 1.72% | 2.39% | Q3 2021 | Q3 2023 | 9 | |
CRSP | CRISPR THERAPEUTICS AG | 9 | 9 | 0.23% | 1.50% | 2.70% | Q4 2018 | Q4 2020 | 9 |
ADXS | ADVAXIS INC | 9 | 9 | 0.24% | 1.22% | 2.18% | Q3 2014 | Q3 2016 | 9 |
WVE | WAVE LIFE SCIENCES PTE... | 9 | 9 | 0.62% | 1.16% | 1.92% | Q4 2015 | Q4 2017 | 9 |
KZR | KEZAR LIFE SCIENCES INC | 6 | 1 | 0.17% | 1.14% | 2.73% | Q2 2018 | Q2 2022 | 9 |
RMTI | ROCKWELL MED INC | 9 | 9 | 0.57% | 1.01% | 1.36% | Q1 2014 | Q1 2016 | 9 |
BEAM | BEAM THERAPEUTICS INC | 9 | 9 | 0.31% | 0.88% | 2.37% | Q1 2020 | Q1 2022 | 9 |
KURA | KURA ONCOLOGY INC | 9 | 9 | 0.37% | 0.82% | 1.58% | Q4 2018 | Q4 2020 | 9 |
DCPH | DECIPHERA PHARMACEUTIC... | 9 | 9 | 0.18% | 0.61% | 1.63% | Q3 2019 | Q3 2021 | 9 |
AMRN | AMARIN CORP PLC | 9 | 9 | 0.05% | 0.60% | 1.23% | Q3 2018 | Q3 2020 | 9 |
ATRA | ATARA BIOTHERAPEUTICS INC | 6 | 3 | 0.26% | 0.58% | 1.48% | Q2 2015 | Q3 2019 | 9 |
CTMX | CYTOMX THERAPEUTICS INC | 8 | 1 | 0.32% | 0.58% | 0.93% | Q4 2015 | Q4 2018 | 9 |
EPZM | EPIZYME INC | 9 | 9 | 0.17% | 0.46% | 0.85% | Q1 2015 | Q1 2017 | 9 |
EIGR | EIGER BIOPHARMACEUTICA... | 9 | 9 | 0.08% | 0.31% | 0.70% | Q2 2019 | Q2 2021 | 9 |
ELDN | ELEDON PHARMACEUTICALS... | 9 | 9 | 0.19% | 0.29% | 0.40% | Q1 2021 | Q1 2023 | 9 |
MRUS | MERUS N V | 9 | 9 | 0.15% | 0.27% | 0.56% | Q4 2019 | Q4 2021 | 9 |
HTGM | HTG MOLECULAR DIAGNOST... | 9 | 9 | 0.05% | 0.14% | 0.30% | Q2 2015 | Q2 2017 | 9 |
GRPH | GRAPHITE BIO INC | 9 | 9 | 0.03% | 0.08% | 0.20% | Q2 2021 | Q2 2023 | 9 |
PRNB | PRINCIPIA BIOPHARMA INC | 8 | 8 | 2.31% | 3.50% | 5.79% | Q3 2018 | Q2 2020 | 8 |
XBI | SPDR SER TR | 4 | 4 | 1.86% | 3.28% | 5.66% | Q1 2019 | Q1 2021 | 8 |
PTI | PROTEOSTASIS THERAPEUT... | 8 | 8 | 1.41% | 3.23% | 6.29% | Q1 2016 | Q4 2017 | 8 |
IFRX | INFLARX NV | 8 | 8 | 0.04% | 3.00% | 6.62% | Q4 2017 | Q3 2019 | 8 |
GLUE | MONTE ROSA THERAPEUTIC... | 8 | 8 | 1.47% | 2.36% | 3.65% | Q2 2021 | Q1 2023 | 8 |
KPTI | KARYOPHARM THERAPEUTIC... | 8 | 8 | 0.51% | 1.93% | 4.75% | Q4 2013 | Q3 2015 | 8 |
GTHX | G1 THERAPEUTICS, INC. | 7 | 1 | 0.06% | 1.91% | 3.94% | Q2 2017 | Q3 2019 | 8 |
RAIN | RAIN THERAPEUTICS INC | 8 | 8 | 0.79% | 1.32% | 1.78% | Q2 2021 | Q1 2023 | 8 |
ACRX | ACELRX PHARMACEUTICALS... | 8 | 8 | 0.41% | 1.25% | 2.46% | Q4 2013 | Q3 2015 | 8 |
GEMP | GEMPHIRE THERAPEUTICS INC | 8 | 8 | 0.50% | 1.10% | 2.04% | Q3 2016 | Q2 2018 | 8 |
VECT | VECTIVBIO HLDG AG | 8 | 8 | 0.65% | 1.01% | 1.47% | Q2 2021 | Q1 2023 | 8 |
OMER | OMEROS CORP | 4 | 2 | 0.16% | 1.00% | 3.56% | Q4 2017 | Q2 2021 | 8 |
PRAX | PRAXIS PRECISION MEDIC... | 6 | 2 | 0.59% | 0.82% | 1.37% | Q4 2020 | Q3 2023 | 8 |
ASTRIA THERAPEUTICS INC | 8 | 8 | 0.07% | 0.54% | 1.64% | Q3 2021 | Q2 2023 | 8 | |
TALS | TALARIS THERAPEUTICS INC | 8 | 8 | 0.06% | 0.49% | 1.08% | Q2 2021 | Q1 2023 | 8 |
ELEV | ELEVATION ONCOLOGY INC | 8 | 8 | 0.12% | 0.41% | 0.87% | Q2 2021 | Q1 2023 | 8 |
RGNX | REGENXBIO INC | 8 | 8 | 0.18% | 0.33% | 0.55% | Q3 2015 | Q2 2017 | 8 |
AVEO | AVEO PHARMACEUTICALS INC | 8 | 8 | 0.06% | 0.17% | 0.37% | Q2 2015 | Q1 2017 | 8 |
NEOS | NEOS THERAPEUTICS INC | 8 | 8 | 0.04% | 0.07% | 0.17% | Q3 2015 | Q2 2017 | 8 |
ONSIZ | ONCOBIOLOGICS INC - CW... | 8 | 8 | 0.00% | 0.02% | 0.06% | Q2 2016 | Q1 2018 | 8 |
IMV | IMV INC | 8 | 8 | 0.01% | 0.02% | 0.03% | Q4 2020 | Q3 2022 | 8 |
RCPT | RECEPTOS INC | 7 | 7 | 2.94% | 7.13% | 12.12% | Q4 2013 | Q2 2015 | 7 |
TANGO THERAPEUTICS INC | 7 | 7 | 1.04% | 1.95% | 3.16% | Q3 2021 | Q1 2023 | 7 | |
OVAS | OVASCIENCE INC | 7 | 7 | 0.30% | 1.62% | 5.09% | Q3 2014 | Q1 2016 | 7 |
CNST | CONSTELLATION PHARMCET... | 7 | 7 | 0.41% | 1.54% | 4.32% | Q3 2018 | Q1 2020 | 7 |
KRTX | KARUNA THERAPEUTICS INC | 7 | 7 | 0.96% | 1.40% | 2.36% | Q1 2022 | Q3 2023 | 7 |
CYTK | CYTOKINETICS INC | 7 | 7 | 0.69% | 1.18% | 1.90% | Q3 2021 | Q1 2023 | 7 |
CLLS | CELLECTIS SA | 7 | 7 | 0.05% | 1.02% | 1.94% | Q1 2015 | Q3 2016 | 7 |
KITE | KITE PHARMA INC | 7 | 7 | 0.48% | 0.84% | 2.27% | Q3 2014 | Q1 2016 | 7 |
ZYNE | ZYNERBA PHARMACEUTICAL... | 7 | 7 | 0.43% | 0.79% | 1.46% | Q3 2015 | Q1 2017 | 7 |
GALT | GALECTIN THERAPEUTICS INC | 7 | 7 | 0.10% | 0.74% | 2.93% | Q1 2014 | Q3 2015 | 7 |
LBIO | LION BIOTECHNOLOGIES INC | 7 | 7 | 0.38% | 0.54% | 0.80% | Q1 2015 | Q3 2016 | 7 |
TRILLIUM THERAPEUTICS INC | 6 | 1 | 0.19% | 0.51% | 1.37% | Q2 2017 | Q3 2020 | 7 | |
MORF | MORPHIC HLDG INC | 5 | 2 | 0.16% | 0.40% | 0.81% | Q3 2020 | Q2 2023 | 7 |
INSM | INSMED INC | 6 | 1 | 0.23% | 0.39% | 0.85% | Q1 2020 | Q3 2023 | 7 |
ICOSAVAX INC | 7 | 7 | 0.14% | 0.33% | 0.58% | Q3 2021 | Q1 2023 | 7 | |
VIGIL NEUROSCIENCE INC | 7 | 7 | 0.12% | 0.32% | 0.52% | Q1 2022 | Q3 2023 | 7 | |
ITOS | ITEOS THERAPEUTICS INC | 7 | 7 | 0.23% | 0.29% | 0.42% | Q3 2020 | Q1 2022 | 7 |
ONS | ONCOBIOLOGICS INC | 7 | 7 | 0.00% | 0.29% | 0.50% | Q2 2016 | Q4 2017 | 7 |
THLD | THRESHOLD PHARMACEUTIC... | 7 | 7 | 0.06% | 0.07% | 0.09% | Q4 2015 | Q2 2017 | 7 |
CLRBW | CELLECTAR BIOSCIENCES INC | 7 | 7 | 0.01% | 0.05% | 0.07% | Q3 2014 | Q1 2016 | 7 |
MOONLAKE IMMUNOTHERAPE... | 6 | 6 | 2.34% | 11.65% | 27.07% | Q2 2022 | Q3 2023 | 6 | |
PBYI | PUMA BIOTECHNOLOGY INC | 6 | 6 | 3.63% | 8.67% | 24.90% | Q4 2013 | Q1 2015 | 6 |
SPY | SPDR S&P 500 ETF TR | 5 | 1 | 4.45% | 7.47% | 11.98% | Q3 2019 | Q1 2021 | 6 |
ARCELLX INC | 6 | 6 | 2.08% | 3.61% | 4.50% | Q2 2022 | Q3 2023 | 6 | |
CMRX | CHIMERIX INC | 6 | 6 | 0.63% | 1.53% | 2.48% | Q4 2013 | Q1 2015 | 6 |
GREENLIGHT BIOSCIENCS ... | 6 | 6 | 0.15% | 1.45% | 4.76% | Q1 2022 | Q2 2023 | 6 | |
IMVT | IMMUNOVANT INC | 3 | 1 | 0.12% | 1.31% | 2.74% | Q3 2020 | Q3 2023 | 6 |
PTCT | PTC THERAPEUTICS INC | 6 | 6 | 0.08% | 0.96% | 3.31% | Q4 2013 | Q1 2015 | 6 |
AKBA | AKEBIA THERAPEUTICS INC | 6 | 6 | 0.14% | 0.91% | 2.95% | Q2 2014 | Q3 2015 | 6 |
COGT | COGENT BIOSCIENCES INC | 6 | 6 | 0.50% | 0.74% | 1.51% | Q2 2022 | Q3 2023 | 6 |
VSAR | VERSARTIS INC | 6 | 6 | 0.31% | 0.68% | 1.49% | Q2 2014 | Q3 2015 | 6 |
HLXA | HELIX ACQUISITION CORP | 6 | 6 | 0.10% | 0.56% | 2.56% | Q4 2020 | Q1 2022 | 6 |
EPRSQ | EPIRUS BIOPHARMACEUTIC... | 6 | 6 | 0.07% | 0.55% | 1.24% | Q4 2014 | Q1 2016 | 6 |
CERU | CERULEAN PHARMA INC | 6 | 6 | 0.32% | 0.46% | 0.69% | Q2 2014 | Q3 2015 | 6 |
KIN | KINDRED BIOSCIENCES INC | 6 | 6 | 0.27% | 0.42% | 0.67% | Q2 2014 | Q3 2015 | 6 |
CYAD | CELYAD SA | 6 | 6 | 0.20% | 0.41% | 0.52% | Q2 2015 | Q3 2016 | 6 |
SRRK | SCHOLAR ROCK HOLDING CORP | 6 | 6 | 0.06% | 0.24% | 0.39% | Q2 2018 | Q3 2019 | 6 |
FOLD | AMICUS THERAPEUTICS INC | 6 | 6 | 0.12% | 0.22% | 0.38% | Q2 2015 | Q3 2016 | 6 |
ITRM | ITERUM THERAPEUTICS PLC | 6 | 6 | 0.14% | 0.22% | 0.40% | Q2 2018 | Q3 2019 | 6 |
CLRB | CELLECTAR BIOSCIENCES INC | 6 | 6 | 0.05% | 0.19% | 0.26% | Q3 2014 | Q4 2015 | 6 |
MGTX | MEIRAGTX HOLDINGS PLC | 3 | 3 | 0.09% | 0.18% | 0.21% | Q2 2018 | Q2 2022 | 6 |
PYXIS ONCOLOGY INC | 6 | 6 | 0.06% | 0.16% | 0.42% | Q4 2021 | Q1 2023 | 6 | |
CLTX | CELSUS THERAPEUTICS PLC | 6 | 6 | 0.02% | 0.15% | 0.31% | Q1 2014 | Q2 2015 | 6 |
SCYX | SCYNEXIS INC | 6 | 6 | 0.12% | 0.15% | 0.21% | Q2 2014 | Q3 2015 | 6 |
VCYT | VERACYTE INC | 6 | 6 | 0.10% | 0.14% | 0.20% | Q4 2014 | Q1 2016 | 6 |
PVCT | PROVECTUS BIOPHARMACEU... | 6 | 6 | 0.02% | 0.12% | 0.20% | Q2 2015 | Q3 2016 | 6 |
PVCTW | PROVECTUS BIOPHARMACEU... | 6 | 6 | 0.01% | 0.06% | 0.11% | Q2 2015 | Q3 2016 | 6 |
ADAP | ADAPTIMMUNE THERAPEUTI... | 6 | 6 | 0.02% | 0.04% | 0.06% | Q2 2015 | Q3 2016 | 6 |
CLRB | CELLECTAR BIOSCIENCES INC | 6 | 6 | 0.01% | 0.02% | 0.03% | Q1 2016 | Q2 2017 | 6 |
NKTR | NEKTAR THERAPEUTICS | 5 | 5 | 0.67% | 5.87% | 12.13% | Q4 2017 | Q4 2018 | 5 |
IWM | ISHARES TR | 5 | 5 | 2.33% | 5.12% | 9.84% | Q2 2020 | Q2 2021 | 5 |
KERX | KERYX BIOPHARMACEUTICA... | 4 | 1 | 1.10% | 2.82% | 6.39% | Q4 2013 | Q2 2015 | 5 |
VIE | VIELA BIO INC | 5 | 5 | 1.22% | 2.03% | 3.11% | Q4 2019 | Q4 2020 | 5 |
DVAX | DYNAVAX TECHNOLOGIES CORP | 5 | 5 | 1.31% | 1.92% | 2.83% | Q2 2015 | Q2 2016 | 5 |
CLVS | CLOVIS ONCOLOGY INC | 4 | 1 | 0.65% | 1.60% | 2.58% | Q4 2013 | Q3 2016 | 5 |
VENTYX BIOSCIENCES INC | 5 | 5 | 0.72% | 1.34% | 2.37% | Q4 2021 | Q4 2022 | 5 | |
NXTC | NEXTCURE INC | 5 | 5 | 0.57% | 1.32% | 2.25% | Q2 2019 | Q2 2020 | 5 |
SLDB | SOLID BIOSCIENCES INC | 5 | 5 | 0.16% | 1.16% | 2.06% | Q1 2018 | Q1 2019 | 5 |
ACET | ADICET BIO INC | 5 | 5 | 0.36% | 1.13% | 1.99% | Q4 2021 | Q4 2022 | 5 |
AVXS | AVEXIS INC | 3 | 2 | 0.32% | 1.07% | 2.32% | Q3 2016 | Q1 2018 | 5 |
KNSA | KINIKSA PHARMACEUTICAL... | 4 | 1 | 0.05% | 0.94% | 1.90% | Q2 2018 | Q1 2021 | 5 |
MCRB | SERES THERAPEUTICS INC | 5 | 5 | 0.28% | 0.91% | 1.18% | Q2 2015 | Q2 2016 | 5 |
QTRX | QUANTERIX CORP | 5 | 5 | 0.08% | 0.81% | 1.90% | Q4 2017 | Q4 2018 | 5 |
JNCE | JOUNCE THERAPEUTICS INC | 5 | 5 | 0.14% | 0.77% | 1.39% | Q1 2017 | Q1 2018 | 5 |
IVTY | INVUITY INC | 5 | 5 | 0.05% | 0.70% | 1.16% | Q2 2016 | Q2 2017 | 5 |
IDYA | IDEAYA BIOSCIENCES INC | 5 | 5 | 0.32% | 0.58% | 0.94% | Q3 2022 | Q3 2023 | 5 |
TYRA BIOSCIENCES INC | 5 | 5 | 0.40% | 0.58% | 0.74% | Q3 2021 | Q3 2022 | 5 | |
ALGS | ALIGOS THERAPEUTICS INC | 5 | 5 | 0.37% | 0.58% | 0.82% | Q4 2020 | Q4 2021 | 5 |
RARX | RA PHARMACEUTICALS INC | 5 | 5 | 0.43% | 0.57% | 0.65% | Q4 2018 | Q4 2019 | 5 |
RUBY | RUBIUS THERAPEUTICS INC | 5 | 5 | 0.24% | 0.52% | 0.80% | Q3 2018 | Q3 2019 | 5 |
SNDX | SYNDAX PHARMACEUTICALS... | 5 | 5 | 0.23% | 0.37% | 0.48% | Q1 2016 | Q1 2017 | 5 |
RPTX | REPARE THERAPEUTICS INC | 5 | 5 | 0.24% | 0.36% | 0.42% | Q2 2020 | Q2 2021 | 5 |
KROS | KEROS THERAPEUTICS INC | 5 | 5 | 0.21% | 0.35% | 0.52% | Q4 2021 | Q4 2022 | 5 |
TCRR | TCR2 THERAPEUTICS INC | 5 | 5 | 0.17% | 0.34% | 0.47% | Q3 2020 | Q3 2021 | 5 |
FIXX | HOMOLOGY MEDICINES INC | 3 | 2 | 0.19% | 0.31% | 0.43% | Q2 2019 | Q3 2020 | 5 |
KDMN | KADMON HOLDINGS INC | 4 | 1 | 0.06% | 0.23% | 0.52% | Q1 2018 | Q1 2021 | 5 |
GTH | GENETRON HLDGS LTD | 5 | 5 | 0.09% | 0.17% | 0.23% | Q2 2020 | Q2 2021 | 5 |
CMMB | CHEMOMAB THERAPEUTICS LTD | 5 | 5 | 0.03% | 0.07% | 0.11% | Q1 2022 | Q1 2023 | 5 |
FATE | FATE THERAPEUTICS INC | 5 | 5 | 0.02% | 0.04% | 0.08% | Q1 2020 | Q1 2021 | 5 |
CELG | CELGENE CORP | 1 | 1 | 1.51% | 4.28% | 5.88% | Q4 2013 | Q1 2016 | 4 |
ARWR | ARROWHEAD RESH CORP | 4 | 4 | 2.73% | 3.26% | 3.78% | Q4 2013 | Q3 2014 | 4 |
BMY | BRISTOL-MYERS SQUIBB CO | 3 | 1 | 1.58% | 3.15% | 4.58% | Q4 2013 | Q1 2015 | 4 |
JUNO | JUNO THERAPEUTICS INC | 4 | 4 | 2.09% | 2.85% | 3.72% | Q1 2017 | Q4 2017 | 4 |
MGNX | MACROGENICS INC | 4 | 4 | 1.85% | 2.22% | 2.71% | Q4 2015 | Q3 2016 | 4 |
CRBP | CORBUS PHARMACEUTICALS... | 4 | 4 | 0.85% | 1.80% | 2.85% | Q2 2016 | Q1 2017 | 4 |
CBAY | CYMABAY THERAPEUTICS INC | 3 | 1 | 0.71% | 1.78% | 3.35% | Q3 2017 | Q3 2023 | 4 |
MRTX | MIRATI THERAPEUTICS INC | 4 | 4 | 0.95% | 1.62% | 2.57% | Q2 2019 | Q1 2020 | 4 |
ASND | ASCENDIS PHARMA A S | 4 | 4 | 1.39% | 1.58% | 1.83% | Q2 2019 | Q1 2020 | 4 |
PCVX | VAXCYTE INC | 4 | 4 | 0.68% | 1.39% | 1.98% | Q4 2022 | Q3 2023 | 4 |
INCR | INC RESH HLDS INC CL A | 4 | 4 | 0.98% | 1.20% | 1.42% | Q2 2016 | Q1 2017 | 4 |
CCXI | CHEMOCENTRYX INC | 4 | 4 | 0.40% | 1.07% | 2.20% | Q4 2019 | Q3 2020 | 4 |
FLGT | FULGENT GENETICS INC | 4 | 4 | 0.79% | 1.03% | 1.34% | Q3 2016 | Q2 2017 | 4 |
INCY | INCYTE CORP | 4 | 4 | 0.17% | 0.91% | 1.30% | Q2 2018 | Q1 2019 | 4 |
ACHN | ACHILLION PHARMACEUTIC... | 4 | 4 | 0.58% | 0.81% | 1.11% | Q4 2015 | Q3 2016 | 4 |
STSA | SATSUMA PHARMACEUTICAL... | 4 | 4 | 0.67% | 0.79% | 0.88% | Q3 2019 | Q2 2020 | 4 |
RIGL | RIGEL PHARMACEUTICALS INC | 4 | 4 | 0.47% | 0.76% | 0.96% | Q3 2016 | Q2 2017 | 4 |
ASPX | AUSPEX PHARMACEUTICALS... | 4 | 4 | 0.53% | 0.66% | 0.81% | Q1 2014 | Q4 2014 | 4 |
AAAP | ADVANCED ACCELERATOR A... | 4 | 4 | 0.43% | 0.57% | 0.90% | Q4 2016 | Q3 2017 | 4 |
BNTX | BIONTECH SE | 4 | 4 | 0.24% | 0.52% | 0.86% | Q2 2020 | Q1 2021 | 4 |
PHAS | PHASEBIO PHARMACEUTICA... | 4 | 4 | 0.21% | 0.43% | 0.68% | Q4 2018 | Q3 2019 | 4 |
BLCM | BELLICUM PHARMACEUTICA... | 2 | 2 | 0.18% | 0.39% | 0.73% | Q4 2014 | Q1 2016 | 4 |
CRVS | CORVUS PHARMACEUTICALS... | 4 | 4 | 0.24% | 0.36% | 0.43% | Q2 2016 | Q1 2017 | 4 |
CNTB | CONNECT BIOPHARMA HLDG... | 4 | 4 | 0.06% | 0.35% | 0.49% | Q1 2021 | Q4 2021 | 4 |
SWTX | SPRINGWORKS THERAPEUTI... | 3 | 1 | 0.04% | 0.34% | 0.88% | Q4 2020 | Q2 2022 | 4 |
TBIO | TRANSLATE BIO, INC | 4 | 4 | 0.28% | 0.33% | 0.42% | Q2 2018 | Q1 2019 | 4 |
TETRALOGIC PHARMACEUTI... | 4 | 4 | 0.17% | 0.31% | 0.42% | Q2 2015 | Q1 2016 | 4 | |
REPL | REPLIMUNE GROUP INC | 2 | 2 | 0.08% | 0.27% | 0.49% | Q3 2018 | Q1 2021 | 4 |
BCTG | BCTG ACQUISITION CORP | 4 | 4 | 0.20% | 0.26% | 0.32% | Q3 2020 | Q2 2021 | 4 |
MRNS | MARINUS PHARMACEUTICAL... | 4 | 4 | 0.14% | 0.25% | 0.43% | Q4 2017 | Q3 2018 | 4 |
AVEO | AVEO PHARMACEUTICALS INC | 2 | 2 | 0.20% | 0.23% | 0.26% | Q2 2020 | Q2 2021 | 4 |
HSAQ | HEALTH SCIENCES ACQ CO... | 4 | 4 | 0.08% | 0.22% | 0.34% | Q3 2020 | Q2 2021 | 4 |
RENOVACOR INC | 4 | 4 | 0.08% | 0.16% | 0.23% | Q3 2021 | Q2 2022 | 4 | |
BITI | BIOTIE THERAPIES OYJ | 4 | 4 | 0.09% | 0.13% | 0.20% | Q2 2015 | Q1 2016 | 4 |
BIOHAVEN LTD | 4 | 4 | 0.07% | 0.10% | 0.12% | Q4 2022 | Q3 2023 | 4 | |
CRDF | CARDIFF ONCOLOGY INC | 4 | 4 | 0.02% | 0.05% | 0.10% | Q3 2020 | Q2 2021 | 4 |
JAZZ | JAZZ PHARMACEUTICALS PLC | 3 | 3 | 3.19% | 3.46% | 3.90% | Q1 2014 | Q3 2014 | 3 |
BLUE | BLUEBIRD BIO INC | 3 | 3 | 1.49% | 3.20% | 4.79% | Q2 2017 | Q4 2017 | 3 |
ALT | ALTIMMUNE INC | 3 | 3 | 2.65% | 2.86% | 3.07% | Q2 2022 | Q4 2022 | 3 |
ACAD | ACADIA PHARMACEUTICALS... | 3 | 3 | 0.30% | 2.59% | 5.80% | Q4 2013 | Q2 2014 | 3 |
ETNB | 89BIO INC | 3 | 3 | 1.43% | 2.14% | 2.81% | Q4 2022 | Q2 2023 | 3 |
ENLIVEN THERAPEUTICS INC | 3 | 3 | 0.97% | 1.99% | 2.79% | Q1 2023 | Q3 2023 | 3 | |
VTAE | VITAE PHARMACEUTICALS INC | 3 | 3 | 1.35% | 1.92% | 2.68% | Q4 2015 | Q2 2016 | 3 |
STRUCTURE THERAPEUTICS... | 3 | 3 | 0.90% | 1.78% | 3.11% | Q1 2023 | Q3 2023 | 3 | |
ZGNX | ZOGENIX INC | 3 | 3 | 1.51% | 1.60% | 1.67% | Q3 2018 | Q1 2019 | 3 |
CCCC | C4 THERAPEUTICS INC | 3 | 3 | 0.46% | 1.47% | 2.05% | Q4 2020 | Q2 2021 | 3 |
BHVN | BIOHAVEN PHARMACTL HLD... | 3 | 3 | 1.09% | 1.33% | 1.52% | Q2 2019 | Q4 2019 | 3 |
GEVA | SYNAGEVA BIOPHARMA CORP | 3 | 3 | 0.64% | 1.16% | 1.43% | Q3 2014 | Q1 2015 | 3 |
EYPT | EYEPOINT PHARMACEUTICA... | 3 | 3 | 0.04% | 1.03% | 1.56% | Q1 2023 | Q3 2023 | 3 |
SGYPQ | SYNERGY PHARMACEUTICAL... | 3 | 3 | 0.81% | 0.98% | 1.23% | Q4 2016 | Q2 2017 | 3 |
ARCT | ARCTURUS THERAPEUTICS ... | 3 | 3 | 0.16% | 0.92% | 1.43% | Q1 2020 | Q3 2020 | 3 |
ARQT | ARCUTIS BIOTHERAPEUTIC... | 2 | 1 | 0.43% | 0.80% | 1.34% | Q3 2022 | Q2 2023 | 3 |
MASS | 908 DEVICES INC | 3 | 3 | 0.58% | 0.67% | 0.72% | Q4 2020 | Q2 2021 | 3 |
DERMTECH INC | 3 | 3 | 0.39% | 0.64% | 0.90% | Q1 2021 | Q3 2021 | 3 | |
SYRS | SYROS PHARMACEUTICALS INC | 3 | 3 | 0.30% | 0.62% | 0.79% | Q2 2017 | Q4 2017 | 3 |
ALBO | ALBIREO PHARMA INC | 3 | 3 | 0.39% | 0.58% | 0.90% | Q3 2020 | Q1 2021 | 3 |
MRSN | MERSANA THERAPEUTICS INC | 3 | 3 | 0.18% | 0.53% | 0.90% | Q2 2017 | Q4 2017 | 3 |
RAPT | RAPT THERAPEUTICS INC | 3 | 3 | 0.32% | 0.48% | 0.79% | Q1 2023 | Q3 2023 | 3 |
SBTX | SILVERBACK THERAPEUTIC... | 3 | 3 | 0.25% | 0.43% | 0.55% | Q4 2020 | Q2 2021 | 3 |
GNFT | GENFIT S A | 3 | 3 | 0.32% | 0.42% | 0.57% | Q1 2019 | Q3 2019 | 3 |
VERU | VERU INC | 3 | 3 | 0.22% | 0.41% | 0.72% | Q1 2021 | Q3 2021 | 3 |
PSTX | POSEIDA THERAPEUTICS INC | 3 | 3 | 0.20% | 0.36% | 0.46% | Q3 2022 | Q1 2023 | 3 |
OVID | OVID THERAPEUTICS INC. | 3 | 3 | 0.23% | 0.32% | 0.39% | Q2 2017 | Q4 2017 | 3 |
XNCR | XENCOR INC | 3 | 3 | 0.26% | 0.29% | 0.36% | Q4 2016 | Q2 2017 | 3 |
TARA | PROTARA THERAPEUTICS INC | 3 | 3 | 0.12% | 0.21% | 0.29% | Q3 2020 | Q1 2021 | 3 |
RACA | THERAPEUTICS ACQUISITI... | 3 | 3 | 0.12% | 0.19% | 0.28% | Q3 2020 | Q1 2021 | 3 |
MGTA | MAGENTA THERAPEUTICS INC | 3 | 3 | 0.14% | 0.15% | 0.16% | Q1 2021 | Q3 2021 | 3 |
VSPRU | VESPER HEALTHCARE ACQS... | 3 | 3 | 0.10% | 0.13% | 0.16% | Q3 2020 | Q1 2021 | 3 |
FVAM | 5 01 ACQUISITION CORP | 3 | 3 | 0.11% | 0.12% | 0.14% | Q4 2020 | Q2 2021 | 3 |
GELESIS HLDGS INC | 3 | 3 | 0.05% | 0.11% | 0.21% | Q1 2022 | Q3 2022 | 3 | |
DNAI | PRONAI THERAPEUTICS INC | 3 | 3 | 0.05% | 0.11% | 0.17% | Q3 2015 | Q1 2016 | 3 |
CEREW | CEREVEL THERAPEUTICS H... | 3 | 3 | 0.01% | 0.01% | 0.02% | Q4 2020 | Q2 2021 | 3 |
ORCHARD THERAPEUTICS PLC | 3 | 3 | 0.01% | 0.01% | 0.01% | Q1 2023 | Q3 2023 | 3 | |
MDVN | MEDIVATION INC | 2 | 2 | 8.88% | 9.50% | 10.13% | Q4 2013 | Q1 2014 | 2 |
CBST | CUBIST PHARMACEUTICALS... | 2 | 2 | 5.05% | 6.52% | 8.00% | Q4 2013 | Q1 2014 | 2 |
RXDX | IGNYTA INC | 2 | 2 | 2.57% | 5.10% | 7.63% | Q2 2017 | Q3 2017 | 2 |
TSRO | TESARO INC | 2 | 2 | 1.27% | 4.41% | 7.56% | Q3 2018 | Q4 2018 | 2 |
IDIX | IDENIX PHARMACEUTICALS... | 2 | 2 | 3.47% | 4.27% | 5.08% | Q4 2013 | Q1 2014 | 2 |
BMRN | BIOMARIN PHARMACEUTICA... | 2 | 2 | 2.04% | 3.37% | 4.70% | Q4 2013 | Q1 2014 | 2 |
GERN | GERON CORP | 2 | 2 | 0.72% | 2.70% | 4.67% | Q4 2013 | Q1 2014 | 2 |
MRK | MERCK & CO. INC NEW | 2 | 2 | 1.53% | 2.07% | 2.61% | Q1 2014 | Q2 2014 | 2 |
RETA | REATA PHARMACEUTICALS INC | 2 | 2 | 1.68% | 1.86% | 2.04% | Q4 2019 | Q1 2020 | 2 |
AMYLYX PHARMACEUTICALS... | 2 | 2 | 1.20% | 1.28% | 1.36% | Q3 2022 | Q4 2022 | 2 | |
VNDA | VANDA PHARMACEUTICALS INC | 2 | 2 | 1.20% | 1.28% | 1.35% | Q1 2018 | Q2 2018 | 2 |
ZNTL | ZENTALIS PHARMACEUTICA... | 2 | 2 | 0.82% | 1.27% | 1.73% | Q2 2023 | Q3 2023 | 2 |
ANAB | ANAPTYSBIO INC | 2 | 2 | 1.00% | 1.21% | 1.42% | Q4 2017 | Q1 2018 | 2 |
HZNP | HORIZON THERAPEUTICS P... | 2 | 2 | 0.81% | 1.21% | 1.61% | Q1 2022 | Q2 2022 | 2 |
SPPI | SPECTRUM PHARMACEUTICA... | 2 | 2 | 0.55% | 1.20% | 1.86% | Q2 2018 | Q3 2018 | 2 |
IMVTU | IMMUNOVANT INC | 2 | 2 | 0.90% | 0.98% | 1.06% | Q4 2019 | Q1 2020 | 2 |
ITCI | INTRA-CELLULAR THERAPI... | 2 | 2 | 0.70% | 0.95% | 1.19% | Q1 2022 | Q2 2022 | 2 |
RYTM | RHYTHM PHARMACEUTICALS... | 2 | 2 | 0.55% | 0.85% | 1.14% | Q2 2023 | Q3 2023 | 2 |
PCRX | PACIRA PHARMACEUTICALS... | 2 | 2 | 0.80% | 0.82% | 0.83% | Q4 2013 | Q1 2014 | 2 |
VKTX | VIKING THERAPEUTICS INC | 2 | 2 | 0.44% | 0.80% | 1.15% | Q4 2022 | Q1 2023 | 2 |
AGIO | AGIOS PHARMACEUTICALS INC | 1 | 1 | 0.30% | 0.78% | 1.26% | Q3 2014 | Q2 2016 | 2 |
ZGNX | ZOGENIX INC | 2 | 2 | 0.74% | 0.77% | 0.81% | Q3 2018 | Q4 2018 | 2 |
PRIME MEDICINE INC | 2 | 2 | 0.60% | 0.75% | 0.91% | Q4 2022 | Q1 2023 | 2 | |
HSACU | HEALTH SCIENCES ACQUST... | 2 | 2 | 0.66% | 0.68% | 0.70% | Q2 2019 | Q3 2019 | 2 |
DISC MEDICINE INC | 2 | 2 | 0.56% | 0.59% | 0.62% | Q2 2023 | Q3 2023 | 2 | |
LIANBIO | 2 | 2 | 0.54% | 0.55% | 0.55% | Q1 2023 | Q2 2023 | 2 | |
AAVL | AVALANCHE BIOTECHNOLOG... | 2 | 2 | 0.46% | 0.50% | 0.54% | Q3 2014 | Q4 2014 | 2 |
CATB | CATABASIS PHARMACEUTIC... | 2 | 2 | 0.39% | 0.47% | 0.54% | Q3 2016 | Q4 2016 | 2 |
NTLA | INTELLIA THERAPEUTICS INC | 2 | 2 | 0.39% | 0.46% | 0.54% | Q4 2020 | Q1 2021 | 2 |
OTIC | OTONOMY INC | 2 | 2 | 0.40% | 0.45% | 0.50% | Q3 2020 | Q4 2020 | 2 |
SNSS | SUNESIS PHARMACEUTICAL... | 2 | 2 | 0.31% | 0.40% | 0.49% | Q4 2016 | Q1 2017 | 2 |
HGEN | HUMANIGEN INC | 2 | 2 | 0.35% | 0.39% | 0.43% | Q1 2021 | Q2 2021 | 2 |
FHTX | FOGHORN THERAPEUTICS INC | 2 | 2 | 0.29% | 0.39% | 0.48% | Q4 2020 | Q1 2021 | 2 |
BRISTOL MYERS SQUIBB CO | 2 | 2 | 0.20% | 0.39% | 0.57% | Q3 2014 | Q4 2014 | 2 | |
CLDX | CELLDEX THERAPEUTICS I... | 1 | 1 | 0.23% | 0.32% | 0.41% | Q4 2021 | Q2 2022 | 2 |
TIG | TIGENIX | 2 | 2 | 0.25% | 0.27% | 0.29% | Q4 2016 | Q1 2017 | 2 |
FDMT | 4D MOLECULAR THERAPEUT... | 2 | 2 | 0.19% | 0.20% | 0.20% | Q4 2020 | Q1 2021 | 2 |
FSDC | FS DEV CORP | 2 | 2 | 0.13% | 0.17% | 0.22% | Q3 2020 | Q4 2020 | 2 |
BLSA | BCLS ACQUISITION CORP | 2 | 2 | 0.12% | 0.12% | 0.13% | Q4 2020 | Q1 2021 | 2 |
PANAU | PANACEA ACQUISITION CORP | 2 | 2 | 0.08% | 0.10% | 0.12% | Q3 2020 | Q4 2020 | 2 |
ARQL | ARQULE INC | 2 | 2 | 0.07% | 0.09% | 0.11% | Q3 2018 | Q4 2018 | 2 |
NUVBWS | NUVATION BIO INC | 2 | 2 | 0.01% | 0.01% | 0.01% | Q1 2021 | Q2 2021 | 2 |
OTLK | OUTLOOK THERAPEUTICS INC | 2 | 2 | 0.00% | 0.00% | 0.00% | Q2 2019 | Q3 2019 | 2 |
QQQ | INVESCO QQQ TR | 1 | 1 | 5.60% | 5.60% | 5.60% | Q4 2020 | Q4 2020 | 1 |
QCOR | QUESTCOR PHARMACEUTICA... | 1 | 1 | 4.90% | 4.90% | 4.90% | Q2 2014 | Q2 2014 | 1 |
ICPT | INTERCEPT PHARMACEUTIC... | 1 | 1 | 3.79% | 3.79% | 3.79% | Q1 2014 | Q1 2014 | 1 |
PRTA | PROTHENA CORP PLC | 1 | 1 | 3.08% | 3.08% | 3.08% | Q1 2014 | Q1 2014 | 1 |
OMEROS CORP | 1 | 1 | 2.86% | 2.86% | 2.86% | Q3 2017 | Q3 2017 | 1 | |
MRTX | MIRATI THERAPEUTICS INC | 1 | 1 | 2.61% | 2.61% | 2.61% | Q3 2019 | Q3 2019 | 1 |
XBI | SPDR SER TR | 1 | 1 | 2.53% | 2.53% | 2.53% | Q2 2022 | Q2 2022 | 1 |
ARKG | ARK ETF TR | 1 | 1 | 2.36% | 2.36% | 2.36% | Q2 2021 | Q2 2021 | 1 |
ARKK | ARK ETF TR | 1 | 1 | 2.22% | 2.22% | 2.22% | Q2 2021 | Q2 2021 | 1 |
CRNX | CRINETICS PHARMACEUTIC... | 1 | 1 | 1.91% | 1.91% | 1.91% | Q3 2023 | Q3 2023 | 1 |
MNKKQ | MALLINCKRODT PUB LTD CO | 1 | 1 | 1.91% | 1.91% | 1.91% | Q2 2014 | Q2 2014 | 1 |
ALKERMES PLC | 1 | 1 | 1.77% | 1.77% | 1.77% | Q4 2013 | Q4 2013 | 1 | |
AMAG | AMAG PHARMACEUTICALS INC | 1 | 1 | 1.76% | 1.76% | 1.76% | Q4 2013 | Q4 2013 | 1 |
PODD | INSULET CORP | 1 | 1 | 1.62% | 1.62% | 1.62% | Q4 2013 | Q4 2013 | 1 |
RAYZEBIO INC | 1 | 1 | 1.53% | 1.53% | 1.53% | Q3 2023 | Q3 2023 | 1 | |
SAGE | SAGE THERAPEUTICS INC | 1 | 1 | 1.43% | 1.43% | 1.43% | Q4 2018 | Q4 2018 | 1 |
OMEROS CORP | 1 | 1 | 1.30% | 1.30% | 1.30% | Q2 2018 | Q2 2018 | 1 | |
ALPN | ALPINE IMMUNE SCIENCES... | 1 | 1 | 1.27% | 1.27% | 1.27% | Q3 2023 | Q3 2023 | 1 |
MARINUS PHARMACEUTICAL... | 1 | 1 | 1.23% | 1.23% | 1.23% | Q3 2023 | Q3 2023 | 1 | |
PUMA BIOTECHNOLOGY INC | 1 | 1 | 1.19% | 1.19% | 1.19% | Q2 2014 | Q2 2014 | 1 | |
RLYP | RELYPSA INC | 1 | 1 | 1.18% | 1.18% | 1.18% | Q2 2016 | Q2 2016 | 1 |
CPXX | CELATOR PHARMACEUTICAL... | 1 | 1 | 1.03% | 1.03% | 1.03% | Q1 2016 | Q1 2016 | 1 |
NVAX | NOVAVAX INC | 1 | 1 | 1.01% | 1.01% | 1.01% | Q1 2021 | Q1 2021 | 1 |
MNLO | MENLO THERAPEUTICS INC | 1 | 1 | 0.94% | 0.94% | 0.94% | Q1 2018 | Q1 2018 | 1 |
VRTX | VERTEX PHARMACEUTICALS... | 1 | 1 | 0.90% | 0.90% | 0.90% | Q2 2019 | Q2 2019 | 1 |
EBS | EMERGENT BIOSOLUTIONS INC | 1 | 1 | 0.87% | 0.87% | 0.87% | Q3 2016 | Q3 2016 | 1 |
BBIO | BRIDGEBIO PHARMA INC | 1 | 1 | 0.78% | 0.78% | 0.78% | Q2 2023 | Q2 2023 | 1 |
CNCE | CONCERT PHARMACEUTICAL... | 1 | 1 | 0.75% | 0.75% | 0.75% | Q4 2016 | Q4 2016 | 1 |
BIIB | BIOGEN IDEC INC | 1 | 1 | 0.70% | 0.70% | 0.70% | Q1 2014 | Q1 2014 | 1 |
LLY | LILLY ELI & CO | 1 | 1 | 0.68% | 0.68% | 0.68% | Q3 2022 | Q3 2022 | 1 |
ISEE | IVERIC BIO INC | 1 | 1 | 0.66% | 0.66% | 0.66% | Q2 2023 | Q2 2023 | 1 |
ISEE | IVERIC BIO INC | 1 | 1 | 0.63% | 0.63% | 0.63% | Q3 2022 | Q3 2022 | 1 |
IMAB | I MAB | 1 | 1 | 0.59% | 0.59% | 0.59% | Q3 2021 | Q3 2021 | 1 |
LIPOCINE INC NEW | 1 | 1 | 0.54% | 0.54% | 0.54% | Q4 2014 | Q4 2014 | 1 | |
NVUS | NOVUS THERAPEUTICS INC | 1 | 1 | 0.51% | 0.51% | 0.51% | Q4 2020 | Q4 2020 | 1 |
OSIR | OSIRIS THERAPEUTICS IN... | 1 | 1 | 0.50% | 0.50% | 0.50% | Q4 2013 | Q4 2013 | 1 |
QURE | UNIQURE NV | 1 | 1 | 0.45% | 0.45% | 0.45% | Q2 2019 | Q2 2019 | 1 |
ALT | ALTIMMUNE INC | 1 | 1 | 0.44% | 0.44% | 0.44% | Q4 2022 | Q4 2022 | 1 |
KALV | KALVISTA PHARMACEUTICA... | 1 | 1 | 0.43% | 0.43% | 0.43% | Q1 2021 | Q1 2021 | 1 |
ZSPH | ZS PHARMA INC | 1 | 1 | 0.40% | 0.40% | 0.40% | Q3 2014 | Q3 2014 | 1 |
IDRA | IDERA PHARMACEUTICALS INC | 1 | 1 | 0.38% | 0.38% | 0.38% | Q1 2014 | Q1 2014 | 1 |
ASNS | ARSANIS INC | 1 | 1 | 0.35% | 0.35% | 0.35% | Q4 2018 | Q4 2018 | 1 |
TVTX | TRAVERE THERAPEUTICS INC | 1 | 1 | 0.34% | 0.34% | 0.34% | Q3 2021 | Q3 2021 | 1 |
XNPT | XENOPORT INC | 1 | 1 | 0.33% | 0.33% | 0.33% | Q4 2013 | Q4 2013 | 1 |
ANNX | ANNEXON INC | 1 | 1 | 0.32% | 0.32% | 0.32% | Q1 2023 | Q1 2023 | 1 |
QTNTW | QUOTIENT LTD | 1 | 1 | 0.26% | 0.26% | 0.26% | Q3 2015 | Q3 2015 | 1 |
BNR | BURNING ROCK BIOTECH LTD | 1 | 1 | 0.26% | 0.26% | 0.26% | Q2 2020 | Q2 2020 | 1 |
CATABASIS PHARMACEUTIC... | 1 | 1 | 0.25% | 0.25% | 0.25% | Q2 2021 | Q2 2021 | 1 | |
EOLS | EVOLUS INC | 1 | 1 | 0.23% | 0.23% | 0.23% | Q1 2018 | Q1 2018 | 1 |
AKCA | AKCEA THERAPEUTICS INC | 1 | 1 | 0.23% | 0.23% | 0.23% | Q3 2018 | Q3 2018 | 1 |
SRNE | SORRENTO THERAPEUTICS INC | 1 | 1 | 0.21% | 0.21% | 0.21% | Q3 2020 | Q3 2020 | 1 |
FULC | FULCRUM THERAPEUTICS INC | 1 | 1 | 0.20% | 0.20% | 0.20% | Q1 2023 | Q1 2023 | 1 |
APLS | APELLIS PHARMACEUTICAL... | 1 | 1 | 0.20% | 0.20% | 0.20% | Q2 2023 | Q2 2023 | 1 |
PORTOLA PHARMACEUTICAL... | 1 | 1 | 0.19% | 0.19% | 0.19% | Q2 2017 | Q2 2017 | 1 | |
LEAP THERAPEUTICS INC | 1 | 1 | 0.19% | 0.19% | 0.19% | Q2 2023 | Q2 2023 | 1 | |
OCUL | OCULAR THERAPEUTIX INC | 1 | 1 | 0.19% | 0.19% | 0.19% | Q2 2023 | Q2 2023 | 1 |
ARYBU | ARYA SCIENCES ACQUISIT... | 1 | 1 | 0.18% | 0.18% | 0.18% | Q2 2020 | Q2 2020 | 1 |
ABBVIE INC | 1 | 1 | 0.16% | 0.16% | 0.16% | Q2 2017 | Q2 2017 | 1 | |
GMTX | GEMINI THERAPEUTICS INC | 1 | 1 | 0.14% | 0.14% | 0.14% | Q1 2021 | Q1 2021 | 1 |
MNTA | MOMENTA PHARMACEUTICAL... | 1 | 1 | 0.14% | 0.14% | 0.14% | Q4 2013 | Q4 2013 | 1 |
CGEM | CULLINAN ONCOLOGY INC | 1 | 1 | 0.14% | 0.14% | 0.14% | Q1 2021 | Q1 2021 | 1 |
DNDNQ | DENDREON CORP | 1 | 1 | 0.13% | 0.13% | 0.13% | Q4 2013 | Q4 2013 | 1 |
TETRALOGIC PHARMACEUTI... | 1 | 1 | 0.12% | 0.12% | 0.12% | Q2 2016 | Q2 2016 | 1 | |
AKTX | AKARI THERAPEUTICS PLC | 1 | 1 | 0.11% | 0.11% | 0.11% | Q3 2015 | Q3 2015 | 1 |
ADVM | ADVERUM BIOTECHNOLOGIE... | 1 | 1 | 0.10% | 0.10% | 0.10% | Q3 2019 | Q3 2019 | 1 |
FPRX | FIVE PRIME THERAPEUTIC... | 1 | 1 | 0.10% | 0.10% | 0.10% | Q4 2013 | Q4 2013 | 1 |
TIL | INSTIL BIO INC | 1 | 1 | 0.08% | 0.08% | 0.08% | Q1 2021 | Q1 2021 | 1 |
ENTA | ENANTA PHARMACEUTICALS... | 1 | 1 | 0.08% | 0.08% | 0.08% | Q4 2013 | Q4 2013 | 1 |
NEUMORA THERAPEUTICS INC. | 1 | 1 | 0.08% | 0.08% | 0.08% | Q3 2023 | Q3 2023 | 1 | |
NUVB | NUVATION BIO INC | 1 | 1 | 0.06% | 0.06% | 0.06% | Q1 2021 | Q1 2021 | 1 |
SONENDO INC | 1 | 1 | 0.05% | 0.05% | 0.05% | Q4 2021 | Q4 2021 | 1 | |
GRCL | GRACELL BIOTECHNOLOGIE... | 1 | 1 | 0.04% | 0.04% | 0.04% | Q1 2021 | Q1 2021 | 1 |
MGEN | MIRAGEN THERAPEUTICS INC | 1 | 1 | 0.04% | 0.04% | 0.04% | Q4 2020 | Q4 2020 | 1 |
LPTX | LEAP THERAPEUTICS INC | 1 | 1 | 0.03% | 0.03% | 0.03% | Q1 2023 | Q1 2023 | 1 |
HERON THERAPEUTICS INC | 1 | 1 | 0.02% | 0.02% | 0.02% | Q3 2015 | Q3 2015 | 1 | |
HARPOON THERAPEUTICS INC | 1 | 1 | 0.01% | 0.01% | 0.01% | Q3 2023 | Q3 2023 | 1 | |
Download |
The securities at the top of the list , including QUOTIENT LTD, ASCENDIS PHARMA A/S, and MINERVA NEUROSCIENCES INC, are the highest-conviction holdings of Cormorant Asset Management, LP.
The conviction is calculated by counting the number of quarters a security has been reported by Cormorant Asset Management, LP. The higher the number, the higher the conviction and longer the holding period.
This page lists all the securities that Cormorant Asset Management, LP owns currently or has owned in the past.